ASX - By Stock
|
PAR |
Re:
Ann: Paradigm Doses First UK Participant in Phase 3 Trial
|
|
kenau
|
31 |
10K |
16 |
26/10/22 |
26/10/22 |
ASX - By Stock
|
31
|
10K
|
16
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Reports Successful Primary Endpoint in Phase 2 Trial
|
|
kenau
|
115 |
63K |
23 |
04/10/22 |
04/10/22 |
ASX - By Stock
|
115
|
63K
|
23
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
kenau
|
276 |
105K |
6 |
11/08/22 |
11/08/22 |
ASX - By Stock
|
276
|
105K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
kenau
|
256 |
108K |
10 |
04/08/22 |
04/08/22 |
ASX - By Stock
|
256
|
108K
|
10
|
|
ASX - By Stock
|
AT1 |
Re:
Media Update
|
|
kenau
|
1.8K |
582K |
3 |
10/02/22 |
10/02/22 |
ASX - By Stock
|
1.8K
|
582K
|
3
|
|
ASX - By Stock
|
AT1 |
Re:
Media Update
|
|
kenau
|
1.8K |
582K |
6 |
10/02/22 |
10/02/22 |
ASX - By Stock
|
1.8K
|
582K
|
6
|
|
ASX - By Stock
|
AT1 |
Re:
Media Update
|
|
kenau
|
1.8K |
582K |
10 |
18/01/22 |
18/01/22 |
ASX - By Stock
|
1.8K
|
582K
|
10
|
|
ASX - By Stock
|
AT1 |
Re:
AT1 FY21 - General Discussion + FA
|
|
kenau
|
2.4K |
761K |
7 |
12/01/22 |
12/01/22 |
ASX - By Stock
|
2.4K
|
761K
|
7
|
|
ASX - By Stock
|
AT1 |
Re:
AT1 FY21 - General Discussion + FA
|
|
kenau
|
2.4K |
761K |
11 |
10/01/22 |
10/01/22 |
ASX - By Stock
|
2.4K
|
761K
|
11
|
|
ASX - By Stock
|
AT1 |
Re:
Ann: Response to ASX Price Query
|
|
kenau
|
7 |
7.2K |
7 |
30/12/21 |
30/12/21 |
ASX - By Stock
|
7
|
7.2K
|
7
|
|
ASX - By Stock
|
AT1 |
Re:
Media Update
|
|
kenau
|
1.8K |
582K |
1 |
29/12/21 |
29/12/21 |
ASX - By Stock
|
1.8K
|
582K
|
1
|
|
ASX - By Stock
|
AT1 |
Re:
Media Update
|
|
kenau
|
1.8K |
582K |
7 |
27/12/21 |
27/12/21 |
ASX - By Stock
|
1.8K
|
582K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: First Quarter Results Presentation
|
|
kenau
|
7 |
3.4K |
21 |
24/11/21 |
24/11/21 |
ASX - By Stock
|
7
|
3.4K
|
21
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm CEO Paul Rennie to transition to Non-Exec Chairman
|
|
kenau
|
49 |
19K |
21 |
22/11/21 |
22/11/21 |
ASX - By Stock
|
49
|
19K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast Q4 Update.... OTAT Imminent!
|
|
kenau
|
92 |
31K |
1 |
19/11/21 |
19/11/21 |
ASX - By Stock
|
92
|
31K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Global Market Research indicates price for Zilosu
|
|
kenau
|
67 |
24K |
13 |
08/11/21 |
08/11/21 |
ASX - By Stock
|
67
|
24K
|
13
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PARADIGM CLEARED FOR PHASE 3 TRIAL BY US FDA
|
|
kenau
|
191 |
73K |
19 |
03/11/21 |
03/11/21 |
ASX - By Stock
|
191
|
73K
|
19
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
kenau
|
150 |
72K |
5 |
01/11/21 |
01/11/21 |
ASX - By Stock
|
150
|
72K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
kenau
|
150 |
72K |
6 |
01/11/21 |
01/11/21 |
ASX - By Stock
|
150
|
72K
|
6
|
|
ASX - By Stock
|
AT1 |
Re:
Media Update
|
|
kenau
|
1.8K |
582K |
4 |
27/10/21 |
27/10/21 |
ASX - By Stock
|
1.8K
|
582K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L Improves Survival in High-Risk Acute GvHD
|
|
kenau
|
116 |
48K |
35 |
18/10/21 |
18/10/21 |
ASX - By Stock
|
116
|
48K
|
35
|
|
ASX - By Stock
|
AT1 |
Re:
Self/home testing thread
|
|
kenau
|
40 |
16K |
3 |
14/10/21 |
14/10/21 |
ASX - By Stock
|
40
|
16K
|
3
|
|
ASX - By Stock
|
AT1 |
Re:
Ann: Pause in Trading
|
|
kenau
|
27 |
10K |
7 |
04/10/21 |
04/10/21 |
ASX - By Stock
|
27
|
10K
|
7
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PARADIGM RECEIVES FEEDBACK FROM US FDA ON IND SUBMISSION
|
|
kenau
|
294 |
114K |
24 |
27/09/21 |
27/09/21 |
ASX - By Stock
|
294
|
114K
|
24
|
|
ASX - By Stock
|
AT1 |
Re:
Media Update
|
|
kenau
|
1.8K |
582K |
4 |
06/09/21 |
06/09/21 |
ASX - By Stock
|
1.8K
|
582K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast 2021 Full Year Financial Results Webcast
|
|
kenau
|
195 |
64K |
15 |
30/08/21 |
30/08/21 |
ASX - By Stock
|
195
|
64K
|
15
|
|
ASX - By Stock
|
AT1 |
Re:
Media Update
|
|
kenau
|
1.8K |
582K |
3 |
27/07/21 |
27/07/21 |
ASX - By Stock
|
1.8K
|
582K
|
3
|
|
ASX - By Stock
|
AT1 |
Re:
Media Update
|
|
kenau
|
1.8K |
582K |
3 |
12/07/21 |
12/07/21 |
ASX - By Stock
|
1.8K
|
582K
|
3
|
|
ASX - By Stock
|
AT1 |
Re:
Media Update
|
|
kenau
|
1.8K |
582K |
2 |
12/07/21 |
12/07/21 |
ASX - By Stock
|
1.8K
|
582K
|
2
|
|
ASX - By Stock
|
AT1 |
Re:
Ann: Access Bio receives FDA clearance for COVID-19 antibody test
|
|
kenau
|
50 |
15K |
8 |
28/06/21 |
28/06/21 |
ASX - By Stock
|
50
|
15K
|
8
|
|
ASX - By Stock
|
AT1 |
Re:
AT1 FY21 - General Discussion + FA
|
|
kenau
|
2.4K |
761K |
2 |
17/03/21 |
17/03/21 |
ASX - By Stock
|
2.4K
|
761K
|
2
|
|
ASX - By Stock
|
AT1 |
Re:
Ann: Investor Presentation
|
|
kenau
|
24 |
7.1K |
7 |
10/03/21 |
10/03/21 |
ASX - By Stock
|
24
|
7.1K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Raises US$110M Led By US Strategic Investor Group
|
|
kenau
|
508 |
170K |
12 |
02/03/21 |
02/03/21 |
ASX - By Stock
|
508
|
170K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Proposed issue of Securities - MSB
|
|
kenau
|
18 |
6.8K |
13 |
02/03/21 |
02/03/21 |
ASX - By Stock
|
18
|
6.8K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
kenau
|
272 |
137K |
1 |
26/02/21 |
26/02/21 |
ASX - By Stock
|
272
|
137K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
kenau
|
272 |
137K |
12 |
26/02/21 |
26/02/21 |
ASX - By Stock
|
272
|
137K
|
12
|
|
ASX - By Stock
|
AT1 |
Re:
Ann: Appendix 4D and Half Year Financial Report
|
|
kenau
|
32 |
9.0K |
1 |
23/02/21 |
23/02/21 |
ASX - By Stock
|
32
|
9.0K
|
1
|
|
ASX - By Stock
|
AT1 |
Re:
Ann: Appendix 4D and Half Year Financial Report
|
|
kenau
|
32 |
9.0K |
7 |
23/02/21 |
23/02/21 |
ASX - By Stock
|
32
|
9.0K
|
7
|
|
ASX - By Stock
|
AT1 |
Re:
AT1 FY21 - General Discussion + FA
|
|
kenau
|
2.4K |
761K |
6 |
15/02/21 |
15/02/21 |
ASX - By Stock
|
2.4K
|
761K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
|
|
kenau
|
1.1K |
308K |
9 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
1.1K
|
308K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
|
|
kenau
|
1.1K |
308K |
13 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
1.1K
|
308K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Webcast
|
|
kenau
|
183 |
94K |
15 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
183
|
94K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
kenau
|
1.0K |
513K |
9 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
513K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
kenau
|
13K |
4.9M |
20 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
13K
|
4.9M
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Corporate Update Webcast
|
|
kenau
|
125 |
54K |
20 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
125
|
54K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Corporate Update Webcast
|
|
kenau
|
125 |
54K |
1 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
125
|
54K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Chart
|
|
kenau
|
4.2K |
3.7M |
5 |
30/11/20 |
30/11/20 |
ASX - By Stock
|
4.2K
|
3.7M
|
5
|
|
ASX - By Stock
|
AT1 |
Re:
Media Update
|
|
kenau
|
1.8K |
582K |
3 |
11/11/20 |
11/11/20 |
ASX - By Stock
|
1.8K
|
582K
|
3
|
|
ASX - By Stock
|
AT1 |
Re:
Ann: Quarterly Activity Report & Appendix 4C - 30 September 2020
|
|
kenau
|
89 |
16K |
6 |
29/10/20 |
29/10/20 |
ASX - By Stock
|
89
|
16K
|
6
|
|
ASX - By Stock
|
AT1 |
Re:
Ann: Quarterly Activity Report & Appendix 4C - 30 September 2020
|
|
kenau
|
89 |
16K |
1 |
29/10/20 |
29/10/20 |
ASX - By Stock
|
89
|
16K
|
1
|
|